Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-777607 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-777607 | DRUG | Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation |
Inclusion Criteria: Part A: * Subjects with advanced or metastatic solid tumors who have either progressed on standard therapy or for whom standard therapy is not known Part B: * Subjects with advanced or metastatic gastroesophageal cancer, HRPrC, HNSCC, or PRCC who have either progressed on sta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-777607 is an investigational small molecule being studied for the treatment of advanced or metastatic solid tumors. It was evaluated in a Phase 1 clinical trial in adult patients with advanced solid tumors. It is not an approved therapy and remains in clinical development.
BMS-777607 targets MET, a receptor tyrosine kinase. It acts as an inhibitor of MET. Targeting MET is intended to interfere with signaling pathways involved in tumor growth and progression in advanced solid tumors.
BMS-777607 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in patients with advanced or metastatic solid tumors.
BMS-777607 is in Phase 1 development. It has been evaluated in a single Phase 1 clinical trial, which is now completed. The drug is investigational and has not been approved for any indication.
BMS-777607 was studied in one Phase 1 trial, NCT00605618, titled Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors. The trial enrolled 8 participants in Australia and is completed, with no active trials ongoing.